Kubist Pharmaceutical Injection with datomycin has resumed imports

On September 26, the State Drug Administration issued the Notice on the Resumption of Imports of Datomycin for Injection by Kubist Pharmaceutical Co., Ltd.
on August 17, 2015, the former State Food and Drug Administration issued the Notice on the Discontinuation of Imports of 3 Varieties, including Live Bilicome (No. 53 of 2015), which decided to stop the import of daptomycin for Injection, an injectable drug produced by Cubist Pharmaceuticals, Inc. Kubist Pharmaceuticals Co., Ltd. filed an application for resumption of imports and accepted a re-inspection of its manufacturing plant (OSO Biopharmaceuticals Manufacturing, LLC.) by the former State Food and Drug Administration. According to the results of the re-inspection and the company's further rectification report, the State Drug Administration considered that its rectification met the relevant requirements, decided to restore Kubist Pharmaceutical Co., Ltd. (in 2016 the company's English name changed to: Cubist Pharmaceuticals, LLC.) injection of datomycin imports, requiring the port Food and Drug Administration from the date of the announcement to resume Kubiste Pharmaceutical Co., Ltd. injection of datomycin import clearance records. (Official website of the State Drug Administration)